UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~July 1931, 2025

Milestone Scientific Inc.

(Exact name of registrant as specified in its charter)


Delaware (State or other jurisdiction of incorporation)		001-14053 (Commission File Number)		13-3545623 (IRS Employer Identification No.)


425 Eagle Rock Avenue Suite 403 Roseland, New Jersey (Address of principal executive offices)		07068 (Zip Code)

Registrant’s telephone number, including area code (973) 535-2717

(Former name or former address, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name on exchange on which registered
Common Stock	MLSS	NYSE American

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Item 5.02 — Departure of ~~Directors~~directors or ~~Certain~~certain ~~Officers~~officers; ~~Election~~election of ~~Directors~~directors; ~~Appointment~~appointment of ~~Certain~~certain ~~Officers~~officers; ~~Compensatory~~compensatory ~~Arrangements~~arrangements of ~~Certain~~certain ~~Officers~~officers

OnEffective ~~May 14~~July 31, 2025, the Board of Directors of Milestone Scientific Inc. (the “Company”) ~~unanimously~~appointed byEric ~~the~~Hines ~~directors~~as inPresident ~~attendance~~and ~~appointed~~Chief ~~Shanth~~Executive ~~Thiyagalingam~~Officer, and as ana ~~independent~~ director of the Company. From July 31, 2025 through December 31, 2025 (the “Initial Term”), Mr. ~~Thiyagalingam~~Hines iswill ~~currently~~be ~~the~~entitled ~~Chief~~to ~~Executive~~base ~~Officer~~compensation at the rate of ~~PainTEQ~~$15,000 aper ~~manufacturer~~month. ofFrom ~~proprietary~~January ~~medical~~1, ~~equipment.~~2026, ~~Prior~~subject to ~~being~~Mr. ~~named PainTEQ~~Hines’s ~~Chief~~continued ~~Executive~~employment ~~Officer,~~at hethe ~~served~~Company asby ~~Chief~~mutual ~~Operating~~agreement ~~Officer~~(the ~~and~~“Extended ~~Chief~~Term”), ~~Commercial Officer~~Mr. ~~Prior~~Hines towill ~~joining~~be ~~PainTEQ,~~entitled heto ~~was~~base ~~General~~compensation ~~Manager~~at ~~APAC~~the ~~Neuromodulation~~rate of ~~Abbott Laboratories~~$25,000 aper ~~multinational~~month. ~~medical~~In ~~device~~addition ~~and~~to ~~healthcare~~his ~~company~~base compensation, ~~from~~Mr. ~~2018~~Hines towill ~~2020,~~be ~~and~~granted ~~Regional~~options ~~Director~~(the of“Signing ~~Nevro~~Bonus ~~Corporation,~~Options”) afor ~~medical~~an ~~device~~aggregate ~~company~~of ~~and~~2,000,000 ~~creator~~shares of ~~HFX~~Common ~~(an~~Stock ~~innovative,~~of ~~evidence-based~~the ~~treatment~~Company. The ~~for~~exercise ~~chronic~~price ~~pain~~ of the ~~trunk~~Signing ~~and/or~~Bonus ~~limbs).~~Options ~~Prior~~will ~~thereto,~~be hethe ~~was~~fair ~~Senior~~market ~~Marketing~~value ~~Manager~~of shares of ~~Stryker~~Common ~~South~~Stock ~~Pacific~~of ~~(2012-2016),~~the aCompany ~~manufacturer~~on the date of ~~proprietary~~grant. ~~medical~~Ten ~~devices,~~percent ~~and~~(10%) ~~Global~~of ~~Cardiac~~the ~~Surgery~~Signing ~~Marketing~~Bonus ~~Manager~~Options ~~(2011-2012)~~will vest on the date of grant and ~~ANZ~~the ~~Atrial~~remaining ~~Fibrillation~~ninety ~~Product~~percent ~~Manager~~(90%) will vest in three (~~2009-2011~~3) equal annual installments of St600,000 shares each. ~~Jude~~In ~~Medical~~addition, ait ~~medical~~is ~~device~~expected ~~company~~that ~~acquired~~Mr. byHines ~~Abbott~~would ~~Laboratories,~~be ~~and~~entitled ato ~~Virology~~receive ~~Specialist~~an ~~Representative~~annual incentive bonus, comprised of (~~2006-2009~~i) atseparate ~~Bristol~~performance-based ~~Meyers~~bonuses; ~~Squibb~~ and (ii) a ~~Medical~~discretionary ~~Representative~~bonus, ~~a(2003-2006)~~each atas ~~Boehringer~~determined ~~Ingelheim~~by the Company’s Compensation Committee, in its sole discretion.

Mr. ~~Thiyagalingam~~Hines ~~received~~most recently served as President of North America at Ex Libris Group (September 2014 - June 2021), a BSglobal inprovider ~~Medical~~of ~~Science~~cloud-based ~~from~~solutions ~~Sydney~~for ~~University~~higher education and libraries. From June 2021 to July 2025, Mr. Hines was involved in ~~2002~~providing consulting services for Alethea, a ~~Masters~~technology start-up company, and also invested in ~~Marketing~~commercial ~~Management~~and ~~from~~personal ~~Macquarie~~real ~~Graduate~~estate ~~School~~ventures. ofPrior ~~Management~~to inhis ~~2010~~role at Ex Libris Group, Mr. Hines held various roles at NICE Systems (October 2004-June 2014), a multinational company that designs and anmanufactures ~~MBA~~smart home security and automation products. Mr. Hines served as Senior Director of Sales at NICE Systems from ~~Macquarie~~October ~~Graduate~~2004 ~~School~~to November 2005, and subsequently served as Vice President of ~~Management~~several inNorth American divisions of NICE Systems from November 2005 through June 2014. Prior thereto, Mr. Hines served as Regional Director of Sales at AMDOCS Clarify CRM (October 2003- October 2004), a provider of customer relationship management (CRM) solutions to the communications industry.

~~Item 7~~Mr.~~01 Regulation~~ FDHines ~~Disclosure~~received a BS in Chemistry from Wake Forest University in 1989 and an MBA in International Business from Xavier University in 1996.

~~The~~Item ~~Company issued a press release on May 19, 2025, announcing the appointment of Shanth Thiyagalingam as an independent director of the Company~~8. ~~The~~01 ~~press~~- ~~release~~Other ~~is attached hereto as Exhibit 99.1 and is incorporated herein by reference.~~Events

On August 1, 2025, the Company issued a press release announcing the appointment of Mr. Hines as Chief Executive Officer. The press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release August 1, 2025

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MILESTONE SCIENTIFIC INC.
Dated: May 19, 2025	By:	/s/Neal Goldman
Dated: August 5, 2025	By:	/s/ Neal Goldman
		Neal Goldman
		Interim Chief Executive Officer

Filing Compare · MILESTONE SCIENTIFIC INC.